Kenacort-T (Triamcinolone Acetonide)

Kenacort‑T, a glucocorticoid, is used to manage inflammatory and immune‑mediated disorders.

• Allergic reactions: provides rapid relief of severe hypersensitivity symptoms.
• Rheumatoid arthritis: reduces joint inflammation and pain during flare‑ups.
• Musculoskeletal inflammation: alleviates pain and swelling in bursitis, tendinitis and similar conditions.

• Triamcinolone acetonide binds to intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus and alters gene transcription. This suppresses pro‑inflammatory cytokine production, inhibits leukocyte migration, and reduces vascular permeability, resulting in potent anti‑inflammatory and immunosuppressive effects.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Injection site pain or irritation.
• Elevated blood glucose levels.
• Mild hypertension.
• Insomnia or mood changes.
• Increased appetite and weight gain.
• Fluid retention or edema.

Serious or Rare Side Effects

• Adrenal suppression leading to cortisol deficiency.
• Severe or opportunistic infections.
• Osteonecrosis of the jaw or long bones.
• Cushingoid appearance with skin thinning.
• Psychosis or severe mood disorders.
• Anaphylactic or severe hypersensitivity reactions.

Careful assessment and monitoring are essential when using Kenacort‑T.

• Infection risk: evaluate for active or latent infections before administration.
• Blood glucose: monitor diabetic patients closely for hyperglycaemia.
• Bone health: consider osteoporosis risk in long‑term or high‑dose therapy.
• Dose minimisation: use the lowest effective dose for the shortest duration possible.
• Contraindications: avoid in patients with systemic fungal infections.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Kenacort‑T may interact with several drug classes, requiring clinical judgement.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole) may increase systemic exposure.
• Live vaccines: risk of inadequate immune response or infection.
• Antidiabetic agents: may require dose adjustment due to hyperglycaemia.
• NSAIDs: combined use raises gastrointestinal bleeding risk.
• Anticoagulants: potential for enhanced anticoagulant effect.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin) may reduce efficacy.
• Diuretics: possible electrolyte disturbances.
• Antihypertensives: may blunt blood pressure control.
• Non‑live vaccines: monitor immune response.
• Herbal supplements (e.g., St John’s wort): may alter steroid metabolism.